Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Endoscopic duodenal mucosal resection found effective in subset of T2D patients

Publish date:: August 6, 2019

Key clinical point: Endoscopic duodenal mucosal resection can elicit clinically relevant improvement in glycemic control without the anatomical disruption seen in bariatric surgery.

Major finding: During follow-up measures taken 24 weeks after their duodenal mucosal resection, hemoglobinA_1c fell by a mean of 10 mmol/mol (P less than .001).

Study details: A multicenter, international, phase 2 study of 37 patients who underwent endoscopic complete duodenal mucosal resection.

Disclosures: The study was funded by Fractyl Laboratories. Dr. van Baar reported having no financial disclosures. Four of the study authors reported having financial relationships with numerous pharmaceutical and device companies.

Citation:

van Baar ACG et al. Gut. 2019 Jul 22. doi: 10.1136/gutjnl-2019-318349.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

‘Modest’ benefit for post-MI T2D glucose monitoring,

Diabetic neuropathic pain linked to brain bioenergic anomalies,